Highlights
- Chimeric is developing a range of cell therapies including CHM 1101, CHM 2101 and others for treatment of cancer
- The company has been granted patent in India spanning its therapies CHM 1101 and CHM 1301
- The Israel Patent Office has issued a notice of allowance for Chimeric's application IL 258670
Chimeric Therapeutics (ASX: CHM) -- an Australian-based listed entity progressing in the clinical stage cell therapy space -- has informed about the grant of patent in India and a notice of allowance in Israel. The Indian Patent Office has granted Chimeric patent for applications of the chimeric antigen receptor technology using chlorotoxin. This also includes company's CHM 1101, and CHM 1301. The latter is in clinical stage and former is in pre-clinical stage.
CHM's CEO and Managing Director has lauded this recent development and commented that the company would progress with expansion of its intellectual property portfolio that underpins Chimeric's CLTX CAR pipeline assets. CHM shares on ASX traded at AU$0.071 at the time of writing, with a market cap of over AU$31 million.
Data source: CHM ASX announcement dated 28 April 2023; Image source: Pixabay.com
The development
According to CHM’s latest announcement, the patent office of India has granted a patent enabling certain applications of company’s chimeric antigen receptor technology with the use of chlorotoxin. The patent also includes CHM’s two cellular therapies, namely CHM 1101, and CHM 1301. The former is a CAR T asset and is in clinical stage, while the latter is a CAR NK asset and is in pre-clinical stage. The Indian patent comes with number IN 424963.
Separately, the patent office of Israel has also issued an Official Notification Prior to Acceptance. This is for Chimeric’s application IL 258670 and is a notice of allowance for the application. Notably, Chimeric Therapeutics has exclusive worldwide license for development and commercialisation of IN 424963, IL 258670, and related patent applications filed in other international jurisdictions.
About Chimeric Therapeutics
CHM is only clinical stage cell therapy developer listed in Australia on the ASX (under ticker CHM) and is working on therapies for treatment of cancer. The Company asserts that cell therapies not just delay the progression of the disease, but are also capable of curing it.
The Company’s portfolio includes two CAR T therapies, alongside the allogeneic NK cell therapy platform. There are two ongoing clinical programs and Chimeric states it is planning to add more programs this year.